Investigational drug · Phase 2
JNJ-90014496
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "JNJ-90014496"
First trial start
2022
Aug 12, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNJ-90014496", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "JNJ-90014496" as an intervention, largest first.
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05421663 · 166 participants · Start Aug 12, 2022 · Primary completion Jul 30, 2041
Drug: JNJ-90014496 · For: Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse
Sites: Duarte, California; Denver, Colorado; Iowa City, Iowa · 32 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Lymphoma, Non-Hodgkin
- CC-99282BMS-986369, GolcadomidePhase 37 trials
Bristol Myers Squibb · Lymphoma, Follicular, Large B-cell Lymphoma, Non-Hodgkin Lymphoma
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- valemetostat tosylateDS-3201bPhase 23 trials
Daiichi Sankyo · Non-small Cell Lung Cancer, Lung Cancer, Relapsed/Refractory Peripheral T-Cell Lymphoma
- rivogenlecleucelBPX-501 T cells, BPX-501Phase 22 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- GSK5926371Phase 21 trial
GSK · Lymphoma, Non-Hodgkin
- JMBI-001Phase 21 trial
Chengdu Anticancer Bioscience, Ltd. · Advance Solid Tumors, Lymphoma, Non-Hodgkin
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.